2. Arlene H S., et al. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. NATURE IMMUNOLOGY. 2007, 8: 239-245.3. Hashem O A., et al. PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clin...
Fallon教授团队分析了健康人以及肥胖患者脂肪组织中PD-L1 mRNA水平，发现肥胖患者的PD-L1表达显著上调，并且PD-L1水平与肥胖程度呈现正相关。流式细胞术分析表明，上调表达PD-L1的细胞主要是ILC2和cDC1细胞。这些数据暗示，在过度肥胖患者会代偿性上调PD-L1的表达水平，以限制脂肪组织炎症的加重。人类肥胖患者脂肪组织I...
这说明DC可以通过PD-L1增强ILC2的抗炎功能。 DC细胞通过PD-L1抑制Th1极化并增强ILC2的抗炎功能 获得以上结果后,Fallon教授团队想知道使用PD-L1抑制剂进行体内治疗会不会影响小鼠的代谢。因此,研究团队给予高脂饮食10周的小鼠PD-L1抑制剂治疗,发现接受治疗的小鼠糖耐量受损更加严重,体重也显著增加,脂肪组织中有更多的...
PD-1/PD-L1通路阻断剂，包括PD-1单克隆抗体(纳武单抗nivolumab,帕博丽珠单抗pembrolizumab，西米单抗cemiplimab)以及PD-L1单克隆抗体(阿特珠单抗atezolizumab,阿维鲁单抗avelumab,德瓦鲁单抗durvalumab)是包括黑色素瘤、乳腺癌、结直肠癌、非小细胞肺癌、小细胞肺癌、肾细胞癌、皮肤鳞状细胞癌以及血液系统肿瘤在内的多种...
图1.PD-1/PD-L1信号通路 参考文献 1. Francisco L M., et al. The PD-1 pathway in tolerance and autoimmunity. Immunological Reviews.2010, 236: 219–42. 2. Arlene H S., et al. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. NATURE IMMUNO...
1. Sun, C., R. Mezzadra, and T. N. Schumacher. 2018. Regulation and Function of the PD-L1 Checkpoint.Immunity48: 434-452. 2. Mezzadra, R., C. Sun, L. T. Jae, R. Gomez-Eerland, E. de Vries, W. Wu, et al. 2017. Identification of CMTM6 and CMTM4 as PD-L1 protein reg...
[1]. Chen Y, et al. Looking for the Optimal PD-1/PD-L1 Inhibitor in Cancer Treatment: A Comparison in Basic Structure, Function, and Clinical Practice. Front Immunol. 2020 May 29;11:1088. [3]. Abdin SM, et al. Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and ...
程序性细胞死亡蛋白1(programmed cell death protein 1,PD-1)/程序性死亡配体1(programmed death-ligand 1,PD-L1)是导致肿瘤免疫逃逸的重要免疫检查点分子,阻断PD-1/PD-L1可以重新激活细胞毒性T细胞对肿瘤的杀伤作用,是一种重要的肿瘤免疫治疗方式。肿瘤细胞中PD...
(AMPK), which in turn, phosphorylates PD-L1 on Ser283, thereby disrupting its interaction with CMTM4 and subsequently triggering PD-L1 degradation. In addition, AMPK phosphorylates EZH2, which disrupts PRC2 function, lea...
抗PD-1和PD-L1免疫检查点治疗(ICT)只对部分癌症患者有持久的反应,所以需要生物标志物来预测非反应者。当前的预测生物标志物如PD-L1过表达、肿瘤突变负荷(TMB)等都有局限性,因此需要改进或找出新的生物标志物。作者发现DDR2表达是小鼠模型中ICT反应的决定因素,并使用遗传和药理方法表明抑制DDR2可以增强小鼠的ICT反应...